drugset
drugset / Trial / NCT04990219

A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis

NCT04990219 ↗

Phase 1 Terminated 37 enrolled H. Lundbeck A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main purpose of this study is to investigate Lu AG06466 as a treatment for spasticity in participants with multiple sclerosis (MS).

Timeline

Start
2021-09-27
Primary completion
2023-01-19
Completion
2023-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lu AG06466 Unknown — Oral

Indications

multiple sclerosis